Cancer Research SABCS Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 68, 3115, May 1, 2008. doi: 10.1158/0008-5472.CAN-07-6377
© 2008 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cao, Y.
Right arrow Articles by Reddel, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, Y.
Right arrow Articles by Reddel, R. R.

Molecular Biology, Pathobiology, and Genetics

Amplification of Telomerase Reverse Transcriptase Gene in Human Mammary Epithelial Cells with Limiting Telomerase RNA Expression Levels

Ying Cao, Lily I. Huschtscha, Amanda S. Nouwens, Hilda A. Pickett, Axel A. Neumann, Andy C-M. Chang, Christian D. Toouli, Tracy M. Bryan and Roger R. Reddel

Children's Medical Research Institute, Westmead, and University of Sydney, Sydney, New South Wales, Australia

Requests for reprints: Roger R. Reddel, Children's Medical Research Institute, 214 Hawkesbury Road, Westmead, Sydney, New South Wales 2145 Australia. Phone: 61-2-9687-2800; Fax: 61-2-9687-2120; E-mail: rreddel{at}cmri.usyd.edu.au.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Activation of telomerase is a crucial step during cellular immortalization, and in some tumors this results from amplification of the human telomerase reverse transcriptase (hTERT) gene. Immortalization of normal human cells has been achieved by transduction with hTERT cDNA under the control of a strong heterologous enhancer/promoter, but this is sometimes an inefficient process, with periods of poor growth or even crisis occurring before immortalization. Here, we showed that normal human mammary epithelial cells expressing exogenous hTERT amplified the transgene extensively and expressed high levels of hTERT mRNA and protein. Paradoxically, the cells had low levels of telomerase activity and very short telomeres, indicating that telomerase activity did not correlate with hTERT expression. These cells contained only ~20 human telomerase RNA (hTR) molecules/cell (compared with ~120 hTR molecules per 293 cell). Expression of exogenous hTR caused increased telomerase activity and telomere lengthening. These data indicate that some hTERT-transduced normal cells may express high levels of the transgene but fail to up-regulate endogenous hTR expression sufficiently to enable expression of robust levels of telomerase activity. [Cancer Res 2008;68(9):3115–23]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Human telomeres are nucleoprotein complexes located at the ends of linear chromosomes (1). They shorten at each cell division, which limits the number of times a cell can divide (2). Telomerase is a ribonucleoprotein enzyme complex that adds telomeric repeat sequences to the ends of chromosomes to counteract this shortening (3). It has recently been found that the active human telomerase enzyme is composed of human telomerase reverse transcriptase (hTERT), human telomerase RNA (hTR), and dyskerin (4): hTERT is the catalytic reverse transcriptase component (5), hTR serves as the RNA template for the addition of telomeric repeats (6), and dyskerin is an RNA-binding protein. Mutations in any of these components may result in dyskeratosis congenita, a human disease syndrome associated with short telomeres (reviewed by Kirwan et al. in ref. 7).

Telomerase is not detectable in most normal human somatic cells, whereas it is expressed in >85% of human tumors (8). How telomerase levels are regulated in these tumors is still poorly understood. A major focus of investigation has been the control of hTERT transcription (reviewed by Horikawa et al. in ref. 9). Amplification of the hTERT gene has been observed in various human cancer cell lines and tumors, and is also thought to be a mechanism of telomerase activation (10–13).

In view of the observations that hTR is ubiquitously expressed (6, 14), whereas hTERT is expressed only in telomerase-positive cells (5), and that expression of exogenous hTERT alone can immortalize normal human cells (15, 16), abundance of hTERT was previously thought to be the sole limiting factor for telomerase activity. Although immortalization of many types of normal human cells has been achieved by transducing them with exogenous hTERT, for some strains of normal human cells, this is an inefficient process, with periods of poor growth or even crisis being experienced before immortalization (17–19). Data are accumulating in support of the notion that hTR levels can also be limiting for telomerase activity. For example, hTR mutations have been found to cause autosomal dominant dyskeratosis congenita (20) and can reduce telomerase activity via haploinsufficiency (21). Furthermore, overexpression of both hTERT and hTR elongates telomeres better than overexpression of hTERT alone in X-linked and autosomal dominant dyskeratosis congenita (22, 23). It has also been shown that concomitant overexpression of hTERT and hTR was necessary to substantially increase telomerase activity in both cancer and primary cells (24). However, none of these studies quantified the number of hTR molecules in the cells. This is important because a previous study has reported that there are 11,000 to 13,500 hTR molecules per cell in the telomerase-negative BJ, IMR90, and SW13 cell strains (25), which would be inconsistent with a limiting role for hTR in light of the 20 to 50 active telomerase molecules per cell in 293 cells (4).

In this study, we explore mechanisms of telomerase activity regulation. Human mammary epithelial cells (HMEC) have been transduced with hTERT in our laboratory, and four independent hTERT-immortalized mass cultures (B80-TERT1, 2, 3a, and 3b) were obtained (26). In the present study, we found that the B80-TERT1 cell line had undergone extensive amplification of the hTERT transgene and was expressing high levels of hTERT mRNA and protein but had low telomerase activity. Furthermore, we showed that hTR levels limit telomerase activity and telomere length in this cell line. More importantly, our quantitation of hTR molecules per cell provides an explanation for why hTR is limiting: the low abundance of hTR (~20 molecules of hTR per cell) is insufficient for significant telomerase activity and telomere maintenance even in the presence of a vast excess of hTERT. To our knowledge, our study is the first to report the low abundance of hTR in telomerase-negative cells (approximately three hTR molecules in each telomerase-negative B80 cell), and that hTR limits telomerase activity and telomere maintenance in the context of hTERT amplification.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cells and cell culture. HMECs were cultured in MCDB 170 medium (Invitrogen) as described previously (26). PA317 packaging cells were grown in Dulbecco's Modified Eagles Medium with 10% fetal bovine serum in a 5% CO2 incubator at 37°C.

Fluorescence in situ hybridization analysis. Chromosome preparations from colcemid-arrested cells were obtained according to standard cytogenetic methods (27). A 3.4-kb full-length hTERT cDNA excised from pCIneo-hTERT plasmid (28) or a 650-bp NH2-terminal hTERT fragment excised from pJJ101-hTERT1-182aa was labeled with bio-16-dUTP using the Biotin-Nick Translation Mix (Roche) according to the manufacturer's instructions. Approximately 30 ng/µL of the full-length hTERT or the 650-bp NH2-terminal hTERT fragment was hybridized onto separately denatured chromosome preparations for 16 to 18 h in a humidified chamber at 37°C. The hybridized probe was detected with Fluorescein Avidin DCS (Vector Laboratories) followed by signal amplification with biotinylated anti-avidin antibody (Vector Laboratories) and another layer of Fluorescein Avidin DCS. Chromosomes were counterstained with diamidino-phenyl-indole-dihydrochloride (DAPI; final concentration, 0.6 µg/mL; Sigma-Aldrich) for chromosome identification, and slides were evaluated on a Leica DMLB fluorescence microscope with appropriate filter sets. Fluorescein and DAPI images were captured separately with a cooled charge-coupled device camera (SPOT2; Diagnostic Instruments), merged using SPOT2 software, and further processed using Adobe Photoshop version 6.0 software.

Southern blot analysis. Genomic DNA was digested with EcoR I and Sal I, separated through a 0.8% agarose gel with Tris-borate-EDTA (TBE) buffer at pH 7.5, and transferred onto Hybond N+ membrane (Amersham Biosciences) by capillary action in 0.4 mol/L NaOH for 4 h. The membrane was blocked in Church buffer [1% bovine serum albumin, 1 mmol/L EDTA, 0.5 mol/L NaPO4 (pH 7.2), and 7% SDS] at 65°C for 1 h, followed by hybridization (in Church buffer at 65°C overnight) with the 3.4-kb full-length hTERT cDNA excised from pCIneo-hTERT plasmid and radiolabeled with {alpha}-32P-dCTP. The membrane was washed twice in 2xSSC/0.1%SDS at 65°C for 20 min, followed by another two washes in 0.2xSSC/0.1%SDS at 65°C for 20 min. Washed membrane was exposed to Kodak BioMax MS X-ray film (Sigma-Aldrich).

Reverse transcriptase-PCR. Total RNA was isolated from cell pellets by using TRI-zol reagent (Invitrogen). One microgram of total RNA was reverse transcribed by using Moloney murine leukemia virus reverse transcriptase (Promega). Taq polymerase (Roche) was used for the amplification. See Supplementary Data for PCR conditions and primer sequences.

Quantitative real-time reverse transcriptase-PCR. The Qiagen RNeasy Mini kit (Qiagen) was used to extract total RNA from cells that had been pelleted by centrifugation. Total RNA (1 µg) was treated with DNase I (Invitrogen), followed by reverse transcription [SuperScript III First-Strand Synthesis System for reverse transcriptase-PCR (RT-PCR); Invitrogen] according to the manufacturer's instructions. Real-time RT-PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) in a Corbett RotorGene-6000 thermal cycler. Cycle parameters were as follows: incubation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the reference gene. Primer pairs were matched for PCR efficiencies. See Supplementary Data for primer sequences.

Northern blot analysis. Total RNA from 5 x 106 or 1 x 107 cells was prepared using an RNeasy Mini kit (Qiagen), TRI-zol reagent (Invitrogen), or phenol/chloroform extraction from whole cell lysate to compare potential yield differences. Total RNA extracted by any of the above methods was precipitated, resuspended in 10 µL of water and 10 µL of formamide loading buffer, followed by heating at 70°C for 5 min, loaded on a 1.5-mm thick 4% polyacrylamide, 8M urea gel, and electrophoresed at 25 W for 1 h in 1x TBE buffer. RNA was transferred onto Hybond N+ membrane (Amersham Biosciences) by electroblotting at 1.5A for 2 h in 0.5x TBE buffer, with the buffer cooled to 4°C. The membrane was crosslinked with 254 nm UV light (Stratalinker; Stratagene) and prehybridized in Church buffer (see above) at 55°C for 1 h, followed by hybridization in Church buffer at 55°C overnight with 32P 5'-end–labeled hTR probe (5'-CGG TGG AAG GCG GCA GGC CGA GGC-3'). The membrane was washed three times in 0.1xSSC/0.1%SDS at 55°C for 10 min, exposed to a phosphor screen, and scanned with a Storm 860 optical scanner with ImageQuant software (Molecular Dynamics).

Western blot analysis. Cell pellets were lysed in freshly made radioimmunoprecipitation assay buffer [10 mmol/L Tris-HCl (pH8.0), 140 mmol/L NaCl, 1% Triton X-100, 0.1% SDS, 1x complete protease inhibitors (Roche), 10 mmol/L phenylmethylsulfonylfluoride, and 0.1% sodium deoxycholate]. Lysates equivalent to 50 µg of protein were separated on an 8% polyacrylamide/SDS gel and transferred to Hybond enhanced chemiluminescence (ECL) nitrocellulose (Amersham Biosciences) by electroblotting. The membrane was blocked with 1x PBS containing 2% skim milk and 0.05% Tween 20 at room temperature for 1 h. The membrane was then incubated with the primary antibody (goat polyclonal anti-hTERT; sc-7215; 1:1,000 dilution; Santa Cruz) in 1xPBS containing 1% skim milk and 0.05% Tween 20 at 4°C overnight. The membrane was washed in 1xPBS containing 0.05% Tween 20, followed by the incubation with the secondary antibody (rabbit anti-goat immunoglobulin horseradish peroxidase; 1:10,000 dilution; DAKO Cytomation) in 1xPBS containing 1% skim milk and 0.05% Tween 20 at room temperature for 1 h. Amersham ECL plus Western blotting detection system (Amersham Biosciences) and high performance chemiluminescence film (Amersham Biosciences) were used for detection.

Direct telomerase activity assay. A direct telomerase activity assay recently developed in our laboratory (29) was used. Cells (1 x 107) were lysed and the lysate was incubated with purified anti-hTERT antibody (4). Protein G/Agarose beads were added and the immunoprecipitate was collected into a microspin column. The beads were washed, and antigenic peptide (4) was mixed with the immunoprecipitate to elute telomerase. The activity of immunopurified telomerase was analyzed as described in Supplementary Data.

Production of retroviruses and infections. hTR construct pBABE-puro-U3-hTR (kindly provided by Dr. Kathleen Collins, Department of Molecular and Cell Biology, University of California, Berkeley, CA) and vector alone (pBABE-puro) were transfected into PA317 packaging cells separately using siPORT XP-1 transfection reagent (Ambion). After 48 h, medium was harvested and filtered through a 0.45-µm membrane, and polybrene (Sigma-Aldrich) was added to a final concentration of 4 µg/mL. B80-TERT1 cells were grown to 50% confluence and then incubated with retroviral supernatant at 37°C for 8 h, followed by incubation with fresh medium overnight. Forty-eight hours after infection, cells were passaged and grown in selection medium containing 0.6 µg/mL puromycin (Sigma-Aldrich). Clones were obtained and maintained in medium containing 0.6 µg/mL puromycin.

Terminal restriction fragment analysis. Hinf I- and Rsa I-digested genomic DNA (1.5 µg) was fractionated on a pulsed-field electrophoresis apparatus (Bio-Rad) as previously described (30). The gel was dried, denatured, and hybridized to a [{gamma}-32P] dATP 5'-end–labeled telomeric oligonucleotide probe, (TTAGGG)3. The gel was exposed to a phosphor screen and scanned with a Storm 860 optical scanner with ImageQuant software. Median telomere length was obtained with Telometric software (31).

See Supplementary Data for Preparation of hTR standards and in vitro hTERT translation.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Amplification of exogenous hTERT in HMECs. Four independent hTERT-immortalized mass cultures B80-TERT1, 2, 3a, and 3b were previously obtained in our laboratory by transfecting B80 HMECs with pCIneo-hTERT (26). In the present study, we detected extensive amplification of hTERT DNA in B80-TERT1 cells by fluorescence in situ hybridization (FISH) analysis of metaphase spreads using both a 3.4-kb full-length hTERT cDNA (Fig. 1A ) and a 650-bp NH2-terminal hTERT probe (data not shown). Amplification of hTERT was observed in every metaphase (Fig. 1A) and interphase nucleus (Supplementary Fig. S1), which indicates that this immortalized cell line has become clonal, although it was originally established as a mass culture. A similar pattern of hybridization in B80-TERT1 cells was also observed by FISH analysis when pCIneo vector alone was used as a probe (data not shown). These observations indicate that the hTERT transgene and its accompanying vector sequence were extensively amplified in B80-TERT1 cells.


Figure 1
View larger version (54K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. hTERT amplification in B80-TERT HMEC lines. A, FISH analysis of B80-TERT1 cells using the full-length hTERT cDNA as a probe. Top, the fluorescein-avidin detection of hTERT (green). Middle, DAPI staining of the nucleus (blue). Bottom, merged picture of hTERT signal and DAPI staining. B, Southern blot analysis of B80, B80-TERT1, 2, 3a, and 3b cells using the full-length hTERT cDNA as a probe. Top, detection of hTERT. Bottom, shows the agarose gel stained with ethidium bromide to indicate DNA loading. Note that only 1 µg of B80-TERT1 DNA was loaded because of the very high hTERT gene copy number in these cells, whereas 10 µg of DNA was loaded for the other cell lines. Untransfected B80 cells are the control.

 
Furthermore, hTERT amplification was also detected in B80-TERT3b cells by FISH analysis (Supplementary Fig. S2), although to a much lesser extent than in B80-TERT1 cells. No hTERT amplification was detectable by FISH in B80-TERT2 or 3a cells (data not shown).

To confirm the hTERT amplification seen by FISH in B80-TERT1 and B80-TERT3b cells, Southern blot analysis was performed using the full-length hTERT cDNA as a probe. A very high hTERT copy number was detected in only 1 µg of B80-TERT1 genomic DNA, whereas only a small amount of hTERT DNA was detected in 10 µg of genomic DNA from B80-TERT2 and B80-TERT3a. An intermediate TERT copy number was observed in B80-TERT3b (Fig. 1B). The genomic DNA was digested with EcoR I and Sal I restriction enzymes, which excise the 3.4-kb hTERT cDNA from plasmid pCIneo-hTERT with which the B80-TERT lines were generated. The presence of a dominant 3.4-kb band (Fig. 1B, top) showed that it was the exogenous hTERT that was amplified. This was confirmed by the observation that a high copy number of the vector backbone was detected in B80-TERT1 cells when the pCIneo vector alone was used as a probe in Southern blot analysis (data not shown).

Correlation between hTERT RNA/protein expression and hTERT gene copy number. Expression of hTERT mRNA was measured by conventional and real-time RT-PCR. As shown in Fig. 2A , the highest level of hTERT mRNA was detected in B80-TERT1 cells, less hTERT mRNA was detected in B80-TERT3b, and the least amount of hTERT mRNA was detected in B80-TERT2 and B80-TERT3a cells. No hTERT mRNA could be detected in untransfected B80 cells. Similar amounts of GAPDH mRNA were detected in all five HMEC cultures (Fig. 2A). Quantitation by real-time RT-PCR is shown in Fig. 2B. No hTERT mRNA was detected in untransfected B80 cells (data not shown). All hTERT immortalized lines showed a significantly higher level of hTERT mRNA compared with telomerase-positive 293 cells, with the highest level of hTERT mRNA detected in B80-TERT1 (>30-fold greater than in 293 cells).


Figure 2
View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. hTERT mRNA and protein expression correlates with hTERT gene copy number. hTERT mRNA expression was detected by RT-PCR (A) and quantitative real-time RT-PCR (B; using GAPDH as the reference gene). Error bars, ranges for duplicate PCR reactions. hTERT protein expression was detected by Western blot using hTERT antibody sc7215 (C). In vitro translated hTERT was used as a positive control in the hTERT Western; it migrates a little more slowly in the gel due to the presence of NH2-terminal tags on the protein. hTERT was not detectable in untransfected B80 cells by either RT-PCR or Western blot. B80 refers to untransfected B80, and 1, 2, 3a, and 3b refer to B80-TERT1, B80-TERT2, B80-TERT3a, and B80-TERT3b cells, respectively.

 
To determine whether hTERT protein is being expressed and whether the protein level correlates with the hTERT gene copy number and hTERT mRNA level, Western blot analysis using an antibody against hTERT was performed, with in vitro translated hTERT as a positive control (Fig. 2C). No hTERT could be detected in untransfected B80 cells (data not shown) and the highest hTERT protein level was found in B80-TERT1 cells. Therefore, we conclude that hTERT copy number in this panel of HMEC cell lines correlates with expression levels of hTERT mRNA and protein.

Lowest telomerase activity and lowest hTR in the highest hTERT-expressing cells. To determine whether hTERT expression correlates with telomerase activity, a direct quantitative telomerase activity assay was performed in all four hTERT-immortalized lines (Fig. 3A and B ). Surprisingly, B80-TERT1 cells had the lowest telomerase activity (32% of the activity in B80-TERT3b cells).


Figure 3
View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Telomerase activity measured by a direct telomerase assay correlates with hTR levels. Telomerase reaction products were analyzed on a 10% denaturing sequencing gel (A). Note only 2.5 x 106 293 cells were assayed, whereas 1 x 107 cells were used for the others. Results from four independent telomerase assays were quantified with ImageQuant software and are shown in B. Columns, mean; bars, SE. No telomerase activity was detected in B80 cells. hTR (C) and DKC1 mRNA (D) levels were measured by real-time RT-PCR. Columns, mean; bars, SE from three separate PCR runs (C). Columns, mean; bars, ranges for duplicate PCR reactions from the same PCR run (D). B80, 1, 2, 3a, and 3b are defined in Fig. 2 legend.

 
hTR levels have previously been shown to limit telomerase activity in hTERT-overexpressing HeLa, HT1080, and normal human lung fibroblasts (24). To determine whether telomerase activity is limited by hTR level in hTERT-immortalized B80 cells, relative hTR level was examined using real-time RT-PCR. As shown in Fig. 3C, the hTERT-transduced B80 cells had increased hTR expression (15- to 51-fold) compared with the untransfected controls. The lowest level of hTR was detected in B80-TERT1 (15-fold increase), and the highest level of hTR was detected in B80-TERT3b (51-fold). Different primer sets gave similar real-time RT-PCR results (Supplementary Fig. S3).

To determine the number of hTR molecules in each cell, we performed both Northern blot analysis and real-time RT-PCR using serially diluted in vitro transcribed hTR as standards. Both assays showed excellent linearity of the standards over the range used (Fig. 4, bottom ). Three Northern blot analyses with 293 cells (using three different methods to extract total RNA to compare potential RNA yield difference; see Materials and Methods section) gave very reproducible results, and the number of hTR molecules in each 293 cell was 123 ± 23 (mean ± SE; data not shown). Northern blot analysis showed that the number of hTR molecules per cell was 23, 28, 43, and 90 in B80-TERT1, 2, 3a, and 3b, respectively (Fig. 4A). A repeat Northern gave a 2-fold lower estimate of hTR molecules per cell (data not shown). Three separate real-time RT-PCR analyses with duplicates in each PCR run gave a slightly higher estimate of hTR copy number as follows: 45, 76, 79, and 148 molecules of hTR in B80-TERT1, 2, 3a, and 3b, respectively, and ~300 molecules of hTR in each 293 cell (Fig. 4B).


Figure 4
View larger version (41K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. hTR molecules per cell determined by both quantitative Northern blot analysis and real-time RT-PCR. A, a representative Northern blot analysis using in vitro transcribed hTR (i.v. hTR) as standards (top). Total RNA from 5 x 106 293 cells and 1 x 107 B80-TERT1, 2, 3a, and 3b cells was loaded on the gel. RC, a recovery control added before RNA precipitation (32P-labeled 100-mer DNA oligonucleotide). About 40% of the RNA was recovered after RNA precipitation (data not shown), which was taken into account when calculating hTR molecules per cell (given beneath the gel) by interpolation from the standard curve shown at bottom. B, hTR ratio (to 293) from a representative real-time RT-PCR analysis (top). The standard curve (bottom) was from the same real-time RT-PCR analysis. hTR molecules per cell calculated from three independent experiments are shown in the right column (mean ± SE). Each RT-PCR reaction used 1 µg total cellular RNA; the number of hTR molecules per cell was adjusted for the proportion of total RNA yield represented by this 1 µg. Serially diluted in vivo hTR was included to make the standard curve (bottom). To achieve similar reverse transcription and PCR efficiency, in vivo hTR was reverse transcribed together with 1 µg of VA13 RNA (hTR-negative; ref. 49), followed by PCR amplification.

 
The ~2-fold difference in hTR molecules per cell quantified by our Northern and real-time RT-PCR could be due to the fact that Northern blot analysis only detects the mature 451 nucleotide hTR, whereas real-time RT-PCR would detect the mature hTR in addition to any form of precursor, incompletely synthesized and even partially degraded hTR, provided the target 150-bp amplicon was intact. There are also some technical reasons that may contribute to the differences between the two methods. For example, the signal to noise ratio may confound quantitation by Northern more than by real-time RT-PCR. In addition, this difference is similar to the 3-fold difference in TLC1 (yeast telomerase RNA) copy number examined by Northern and real-time RT-PCR analysis (32). We consider that the copy number of functional hTR molecules is more likely to correspond to the number obtained by Northern because this technique detects the mature full-length hTR. Regardless of which technique is more accurate, the data indicate that telomerase activity correlates with hTR, rather than with hTERT expression levels in these hTERT-overexpressing HMECs.

As dyskerin (encoded by the DKC1 gene) is part of the active telomerase enzyme in addition to hTERT and hTR (4), we examined DKC1 mRNA expression to determine whether DKC1 level correlates with levels of hTERT, hTR, or telomerase activity. As shown in Fig. 3D, hTERT overexpression resulted in increased DKC1 expression from 2- to 4-fold in the four B80-TERT lines. However, no consistent correlation was found between expression of DKC1 mRNA and either hTERT or hTR expression, or telomerase activity.

Increased telomerase activity and telomere lengthening resulted from hTR overexpression. We next addressed whether overexpression of hTR would increase telomerase activity in B80-TERT1 cells. An hTR-containing retroviral vector, pBABE-U3-hTR, was used to induce hTR expression, with pBABE vector alone as a control. B80-TERT1 cells were infected with the retrovirus and selected with puromycin. Individual colonies were picked and cultured for further analysis. Seven hTR-overexpressing clones (hTR15, hTR17, and hTR19-23), three pBABE vector-alone clones (BABE2, BABE6, and BABE8), and parental B80-TERT1 cells were examined for hTR, hTERT, and DKC1 expression using real-time RT-PCR.

In the hTR-infected cells, hTR was overexpressed from 35- to 125-fold compared with parental B80-TERT1 cells, whereas in the vector control clones, hTR levels varied from 0.8- to 1.9-fold compared with the parental cells (Fig. 5A ). The difference in hTR level between hTR-infected and vector control clones was highly significant (P < 0.0001). hTERT expression varied from 1.2- to 4.3-fold in the three vector control clones and from 1- to 6.1-fold in the seven hTR-overexpressing clones compared with parental B80-TERT1 cells (Fig. 5B). DKC1 RNA expression varied from 1.5- to 2.7-fold in the three vector control clones and from 1.7- to 3-fold in the seven hTR-overexpressing clones (Fig. 5C). No significant difference was observed in either hTERT level (P = 0.68) or DKC1 level (P = 0.25) between hTR-infected and vector control clones (Fig. 5).


Figure 5
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. hTR, hTERT mRNA, and DKC1 mRNA expression in hTR-overexpressing B80-TERT1 clones quantitated by real-time RT-PCR. The log of ratios to parental B80-TERT1 cells is presented on the Y-axis. Columns, mean; bars, ranges for duplicate PCR reactions. Unpaired t test was used to compare BABE empty vector control clones (n = 3) and hTR-transduced clones (n = 7). P values are shown in each panel.

 
To measure telomerase activity levels, we used a direct telomerase activity assay. Telomerase activity was increased from 33- to 63-fold in hTR-overexpressing clones in comparison with 1.1- to 1.6-fold in vector-alone controls (Fig. 6A ). We then determined whether the increased telomerase activity resulting from hTR overexpression in B80-TERT1 cells would cause telomere lengthening. As shown in Fig. 6B, B80-TERT1 cells had very short telomeres (median telomere length, 5 kb), whereas B80-TERT3b cells had very long telomeres (median telomere length, 14 kb), correlating with the telomerase activities in those cells (Fig. 3A). As expected, all hTR-overexpressing clones had extensively elongated telomeres (median telomere length varied from 29–36 kb in 7 hTR-overexpressing clones; Fig. 6B), compared with the vector controls that exhibited short telomeres (median telomere length varied from 4.5–5.2 kb in three vector control clones), similar to the parental B80-TERT1 cells. We therefore conclude that hTR overexpression in B80-TERT1 cells resulted in increased telomerase activity and consequent telomere lengthening.


Figure 6
View larger version (61K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. hTR overexpression in B80-TERT1 results in increased telomerase activity and elongated telomeres. Telomerase assay products were analyzed on a 10% denaturing sequencing gel (A). Note that only 2.5 x 106 293 cells were assayed, whereas 1 x 107 cells were used for the others. Telomere length was measured by terminal restriction fragment (TRF) analysis using pulsed field gel electrophoresis (B). HeLa and GM847 are examples of telomerase-positive and Alternative Lengthening of Telomeres–positive cells, respectively. The correlation between telomerase activity and median telomere restriction fragment length is shown in C (the correlation value R was obtained using MS Excel software); points, mean values for three BABE clones and seven hTR clones; bars, SE.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
hTERT amplification has previously been observed in human cancer cell lines (10), neuroblastomas, and tumors of lung, cervix, and breast (10–13). There seems to be an inconsistent relationship between amplification of the hTERT gene and the levels of hTERT mRNA, protein expression, and telomerase activity (10–13). Our study has identified a reason for lack of correlation between hTERT expression levels and telomerase activity, namely inadequate up-regulation of hTR expression.

There was a very low abundance of hTR in telomerase-negative B80 cells before hTERT overexpression, approximately three molecules per cell as measured by real-time RT-PCR (and undetectable by Northern blot; data not shown). Therefore, even a 15-fold up-regulation of hTR in B80-TERT1 (Fig. 3C) was associated with a telomerase activity level that resulted only in maintenance of very short telomeres. That hTR levels were limiting in the B80-TERT1 cells was confirmed by showing that expression of exogenous hTR resulted in high levels of telomerase activity and very long telomeres.

Although until recently it has been assumed that telomerase activity is controlled solely by the availability of hTERT, data are accumulating in support of the notion that hTR and hTERT are both limiting. Notably, overexpression of both hTR and hTERT in HeLa cells and fibroblasts resulted in high levels of telomerase activity and massive telomere elongation (24). Moreover, the important contribution of hTR levels to telomerase activity is indicated by the long-standing observation that hTR levels are substantially elevated in a wide variety of human tumors (33–37) and immortal human cell lines (5). hTR amplification has also been observed in various tumors (38–40), and it may be one mechanism of increased hTR expression in the tumors. More recently, a viral form of telomerase RNA (vTR) with 88% homology to chicken telomerase RNA was found to be encoded by oncogenic strains of Marek's disease virus (MDV) but not by nononcogenic MDV strains (41). Furthermore, the wild-type vTR was shown to facilitate avian tumorigenesis (42). More importantly, the decreased hTR levels observed in human dyskeratosis congenita patients due either to hTR or DKC1 mutations are associated with abnormally short telomeres (reviewed by Kirwan et al. in ref. 7), which can be rescued by overexpression of both hTERT and hTR (22, 23). It seems that the hTR mutations associated with dyskeratosis congenita reduce telomerase activity via haploinsufficiency (21). Studies in mice also suggest telomerase RNA can be limiting (43, 44).

However, none of the above mentioned studies quantitated the number of hTR molecules per cell. It has been suggested that there are 20 to 50 active telomerase molecules per cell in 293 cells (4). B80-TERT1 cells are predicted to have many more molecules of hTERT per cell than 20 to 50 because hTERT is readily detectable by our Western conditions in this cell line (Fig. 2C) and not in 293 cells (data not shown). Thus, our quantification of hTR molecules per cell explains the very short telomeres maintained by this very large number of hTERT molecules: ~20 molecules of hTR are insufficient for significant telomere elongation (Fig. 6B), even in the presence of a vast excess of hTERT.

A previous study has reported that there are 11,000 to 13,500 hTR molecules per cell in the telomerase-negative BJ, IMR90, and SW13 cell strains (25). Assuming that other normal human somatic cells have hTR levels within an order of magnitude of the levels in HMECs, our estimate of approximately three molecules of hTR per B80 cell is more consistent than the previous study (25) with the observation that a 2-fold change of hTR abundance (hTR haploinsufficiency) can lead to dyskeratosis congenita (reviewed by Marrone et al. in ref. 45) because a 2-fold decrease in a vast excess of hTR would not be expected to affect telomere length. Our study is also in agreement with the observation of a low TLC1 abundance in yeast (32). The reason for the discrepancy between our data and those of Yi et al. (25) is likely to be technical rather than an intrinsic difference between B80 cells on the one hand and telomerase-negative BJ, IMR90, and SW13 cells on the other because hTR levels were quantitated in 293 cells in both studies and reported to be 120 to 300 molecules per cell (Northern and real-time RT-PCR; this study) and ~69,000 molecules per cell (competitor RNA RT-PCR method; ref. 25). The number of RNA molecules per cell reported here may be an underestimate due to the yield of RNA during cell extraction being <100%, but this is unlikely to account for a 200- to 600-fold difference; furthermore, three different methods of RNA extraction gave similar results (see Materials and Methods).

The limiting hTR levels in the B80-TERT1 cells may have been the selection pressure that resulted in a growth advantage for a clone of cells within the original mass culture that had acquired amplification of hTERT. Before amplification of hTERT, it is possible that the cellular or local concentrations of both molecules were below the Kd for the interaction, in which case, a higher hTERT concentration would favor the interaction between the molecules and lead to increased telomerase activity, regardless of stoichiometry. Another possibility is that before amplification, hTERT may have been poorly expressed, as it is in B80-TERT3a (Fig. 2C), such that the number of hTERT molecules was lower than hTR, and this limiting hTERT expression may have selected for amplification of hTERT. Alternatively, cells with increased hTERT may have a growth advantage due to putative telomere length-independent functions of hTERT (46, 47).

Up-regulation of hTR has previously been observed in cells expressing exogenous hTERT (22, 23, 48). The increased hTR was suggested to be due to an increased half-life as a result of the association of hTR with hTERT (48). Our results indicate that this cannot be the whole explanation because the cells with the highest hTERT protein levels had the lowest hTR levels.

We found a very consistent correlation between telomere length and telomerase activity (Fig. 6C) as measured by the direct telomerase activity assay. This assay includes a step in which telomerase is partially purified by immunoprecipitation from cell extracts with an hTERT antibody, which greatly increases the sensitivity of the assay (e.g., telomerase activity was readily detectable in 2.5 x 106 293 cells without overexpression of hTR or hTERT). In the series of cell lines generated from B80 cells, the rank order according to telomerase activity was the same as that for telomere length, and in the hTR-transduced B80-TERT1 cells, up-regulation of telomerase activity was accompanied by a corresponding increase in telomere length. In agreement with data from a previous study (24), this indicates that in human cells, telomerase activity level is a major determinant of telomere length.

Our observation that hTERT amplification correlates with hTERT mRNA/protein expression but not telomerase activity in hTERT-immortalized HMECs indicates that hTERT amplification and hTERT expression are not good surrogate markers for telomerase activity levels. Insufficient hTR up-regulation could be one of the explanations for the previously observed nonassociation between hTERT amplification and telomerase activity in some tumors (10–13). Our study is the first to examine the expression of other telomerase components, hTR and dyskerin, in the context of hTERT-immortalized HMECs, and provides further direct evidence that hTR is limiting for telomerase activity and telomere length maintenance. Furthermore, our quantitation of hTR levels (approximately three hTR molecules per cell in telomerase-negative B80 cells) provides an explanation for this observation, which was at odds with the previously reported vast excess of hTR in telomerase-negative cells.


   Acknowledgments
 
Grant support: National Health and Medical Research Council (NHMRC) Peter Doherty Postdoctoral Fellowships (228413, Y. Cao; 228412, A.S. Nouwens), NHMRC Healthy Ageing Research Grant (219306, L.I. Huschtscha and R.R. Reddel), and a Wellcome Trust Senior Research Fellowship (GRO66727MA, T.M. Bryan).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Kathleen Collins for the construct pBABE-puro-U3-hTR; Karen MacKenzie and Laura Veas for the hTR2 and B2M primers; Julie Jurczyluk for the construct pJJ101-hTERT1-182aa, in vitro transcribed hTR, and technical assistance; Scott Cohen for the construct pUC-hTR and the direct telomerase activity assay; and Jeremy Henson, Akira Nguyen, Ze Huai Zhong, Jane Noble, and Elizabeth Collins for technical assistance and advice.


   Footnotes
 
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Current address for A.S. Nouwens: School of Molecular and Microbial Sciences, and Australian Institute of Biotechnology and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia; Current address for C.D. Toouli, Bio-Link Partners Ltd., Suite 7/G11, Locomotive Workshop, Australian Technology Park, Eveleigh, New South Wales 1430, Australia.

Received 11/25/07. Revised 2/ 7/08. Accepted 2/21/08.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988;85:6622–6.[Abstract/Free Full Text]
  2. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458–60.[CrossRef][Medline]
  3. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405–13.[CrossRef][Medline]
  4. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 2007;315:1850–3.[Abstract/Free Full Text]
  5. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955–9.[Abstract/Free Full Text]
  6. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995;269:1236–41.[Abstract/Free Full Text]
  7. Kirwan M, Dokal I. Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 2008;73:103–12.[Medline]
  8. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–5.[Abstract/Free Full Text]
  9. Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003;24:1167–76.[Abstract/Free Full Text]
  10. Zhang A, Zheng C, Lindvall C, et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res 2000;60:6230–5.[Abstract/Free Full Text]
  11. Fan X, Wang Y, Kratz J, et al. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol 2003;162:1763–9.[Abstract/Free Full Text]
  12. Palmqvist R, Zhang A, Xu D, et al. hTERT gene copy number is not associated with hTERT RNA expression or telomerase activity in colorectal cancer. Int J Cancer 2005;116:395–400.[CrossRef][Medline]
  13. Zhu CQ, Cutz JC, Liu N, et al. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer 2006;94:1452–9.[CrossRef][Medline]
  14. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996;56:645–50.[Abstract/Free Full Text]
  15. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349–52.[Abstract/Free Full Text]
  16. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279–82.[CrossRef][Medline]
  17. MacKenzie KL, Franco S, May C, Sadelain M, Moore MA. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Res 2000;259:336–50.[CrossRef][Medline]
  18. Noble JR, Zhong ZH, Neumann AA, Melki JR, Clark SJ, Reddel RR. Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. Oncogene 2004;23:3116–21.[CrossRef][Medline]
  19. Wen VW, Wu K, Baksh S, et al. Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53-competent immortal endothelial cells. Cancer Res 2006;66:10691–700.[Abstract/Free Full Text]
  20. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413:432–5.[CrossRef][Medline]
  21. Marrone A, Stevens D, Vulliamy T, Dokal I, Mason PJ. Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. Blood 2004;104:3936–42.[Abstract/Free Full Text]
  22. Wong JM, Collins K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev 2006;20:2848–58.[Abstract/Free Full Text]
  23. Westin ER, Chavez E, Lee KM, et al. Telomere restoration and extension of proliferative lifespan in dyskeratosis congenita fibroblasts. Aging Cell 2007;6:383–94.[CrossRef][Medline]
  24. Cristofari G, Lingner J. Telomere length homeostasis requires that telomerase levels are limiting. EMBO J 2006;25:565–74.[CrossRef][Medline]
  25. Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 2001;29:4818–25.[Abstract/Free Full Text]
  26. Toouli CD, Huschtscha LI, Neumann AA, et al. Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. Oncogene 2002;21:128–39.[CrossRef][Medline]
  27. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 2001;21:3862–75.[Abstract/Free Full Text]
  28. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTa splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000;2:426–32.[CrossRef][Medline]
  29. Cohen SB, Reddel RR. A sensitive direct human telomerase activity assay. Nat Methods. In press 2008.
  30. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240–8.[Medline]
  31. Grant JD, Broccoli D, Muquit M, Manion FJ, Tisdall J, Ochs MF. Telometric: a tool providing simplified, reproducible measurements of telomeric DNA from constant field agarose gels. Biotechniques 2001;31:1314–8.[Medline]
  32. Mozdy AD, Cech TR. Low abundance of telomerase in yeast: implications for telomerase haploinsufficiency. RNA 2006;12:1721–37.[Abstract/Free Full Text]
  33. Soder AI, Going JJ, Kaye SB, Keith WN. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene 1998;16:979–83.[CrossRef][Medline]
  34. Heine B, Hummel M, Demel G, Stein H. Demonstration of constant upregulation of the telomerase RNA component in human gastric carcinomas using in situ hybridization. J Pathol 1998;185:139–44.[CrossRef][Medline]
  35. Paradis V, Dargere D, Laurendeau I, et al. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue. J Pathol 1999;189:213–8.[CrossRef][Medline]
  36. Yashima K, Litzky LA, Kaiser L, et al. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 1997;57:2373–7.[Abstract/Free Full Text]
  37. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998;83:652–9.[CrossRef][Medline]
  38. Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997;14:1013–21.[CrossRef][Medline]
  39. Heselmeyer-Haddad K, Janz V, Castle PE, et al. Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 2003;163:1405–16.[Abstract/Free Full Text]
  40. Andersson S, Wallin KL, Hellstrom AC, et al. Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer 2006;95:331–8.[CrossRef][Medline]
  41. Fragnet L, Blasco MA, Klapper W, Rasschaert D. The RNA subunit of telomerase is encoded by Marek's disease virus. J Virol 2003;77:5985–96.[Abstract/Free Full Text]
  42. Trapp S, Parcells MS, Kamil JP, et al. A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis. J Exp Med 2006;203:1307–17.[Abstract/Free Full Text]
  43. Hathcock KS, Hemann MT, Opperman KK, Strong MA, Greider CW, Hodes RJ. Haploinsufficiency of mTR results in defects in telomere elongation. Proc Natl Acad Sci USA 2002;99:3591–6.[Abstract/Free Full Text]
  44. Chiang YJ, Hemann MT, Hathcock KS, et al. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 2004;24:7024–31.[Abstract/Free Full Text]
  45. Marrone A, Walne A, Dokal I. Dyskeratosis congenita: telomerase, telomeres and anticipation. Curr Opin Genet Dev 2005;15:249–57.[CrossRef][Medline]
  46. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002;99:12606–11.[Abstract/Free Full Text]
  47. Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002;21:3130–8.[CrossRef][Medline]
  48. Yi X, Tesmer VM, Savre-Train I, Shay JW, Wright WE. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol Cell Biol 1999;19:3989–97.[Abstract/Free Full Text]
  49. Bryan TM, Marusic L, Bacchetti S, Namba M, Reddel RR. The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum Mol Genet 1997;6:921–6.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cao, Y.
Right arrow Articles by Reddel, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, Y.
Right arrow Articles by Reddel, R. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online